Explore

Trendline Trendline
ImmunityBio Faces Securities Fraud Class Action Over Misleading Claims on Cancer Drug

ImmunityBio Faces Securities Fraud Class Action Over Misleading Claims on Cancer Drug

ImmunityBio Faces Securities Fraud Class Action Over Misleading Claims on Cancer Drug
Trendline Trendline
Powerchip Semiconductor Reports Strong Q1 2026 Profit Growth Amid High Demand

Powerchip Semiconductor Reports Strong Q1 2026 Profit Growth Amid High Demand

Powerchip Semiconductor Reports Strong Q1 2026 Profit Growth Amid High Demand
Trendline Trendline
Rosen Law Firm Investigates Disc Medicine Following FDA Rejection of Drug Application

Rosen Law Firm Investigates Disc Medicine Following FDA Rejection of Drug Application

Rosen Law Firm Investigates Disc Medicine Following FDA Rejection of Drug Application
Trendline Trendline
Rosen Law Firm Investigates Disc Medicine, Inc. for Potential Securities Claims

Rosen Law Firm Investigates Disc Medicine, Inc. for Potential Securities Claims

Rosen Law Firm Investigates Disc Medicine, Inc. for Potential Securities Claims
Trendline Trendline
Rosen Law Firm Investigates Disc Medicine for Potential Securities Claims Following FDA Rejection

Rosen Law Firm Investigates Disc Medicine for Potential Securities Claims Following FDA Rejection

Rosen Law Firm Investigates Disc Medicine for Potential Securities Claims Following FDA Rejection
Trendline Trendline
Moderna Stock Fluctuates Amid Hantavirus Vaccine Development Concerns

Moderna Stock Fluctuates Amid Hantavirus Vaccine Development Concerns

Moderna Stock Fluctuates Amid Hantavirus Vaccine Development Concerns
Trendline Trendline
Gossamer Bio Investors Encouraged to Join Securities Class Action Before Deadline

Gossamer Bio Investors Encouraged to Join Securities Class Action Before Deadline

Gossamer Bio Investors Encouraged to Join Securities Class Action Before Deadline
Trendline Trendline
Verastem Oncology Reports $18.7 Million Revenue in Q1 2026 Amid New Clinical Trials

Verastem Oncology Reports $18.7 Million Revenue in Q1 2026 Amid New Clinical Trials

Verastem Oncology Reports $18.7 Million Revenue in Q1 2026 Amid New Clinical Trials
Trendline Trendline
McKesson's Q1 Revenue Falls Short Amidst Margin Initiatives

McKesson's Q1 Revenue Falls Short Amidst Margin Initiatives

McKesson's Q1 Revenue Falls Short Amidst Margin Initiatives
Trendline Trendline
McKesson Reports Q1 Revenue Miss Amidst Margin Initiatives

McKesson Reports Q1 Revenue Miss Amidst Margin Initiatives

McKesson Reports Q1 Revenue Miss Amidst Margin Initiatives
Trendline Trendline
Arrowhead Pharmaceuticals Reports Strong Fiscal 2026 Second Quarter Results Amid Expanding RNAi Therapeutics

Arrowhead Pharmaceuticals Reports Strong Fiscal 2026 Second Quarter Results Amid Expanding RNAi Therapeutics

Arrowhead Pharmaceuticals Reports Strong Fiscal 2026 Second Quarter Results Amid Expanding RNAi Therapeutics
Trendline Trendline
Exelixis to Webcast Fireside Chats at Major Investor Conferences in May 2026

Exelixis to Webcast Fireside Chats at Major Investor Conferences in May 2026

Exelixis to Webcast Fireside Chats at Major Investor Conferences in May 2026